Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011.
The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Candidemia is common and associated with high morbidity and mortality; changes in population-based incidence rates have not been reported. METHODS: We conducted active, population-based surveillance in metropolitan Atlanta, Georgia, and Baltimore City/County, Maryland (combined population 5.2 million), during 2008-2011. We calculated candidemia incidence and antifungal drug resistance compared with prior surveillance (Atlanta, 1992-1993; Baltimore, 1998-2000). RESULTS: We identified 2675 cases of candidemia with 2329 isolates during 3 years of surveillance. Mean annual crude incidence per 100 000 person-years was 13.3 in Atlanta and 26.2 in Baltimore. Rates were highest among adults aged ≥65 years (Atlanta, 59.1; Baltimore, 72.4) and infants (aged <1 year; Atlanta, 34.3; Baltimore, 46.2). In both locations compared with prior surveillance, adjusted incidence significantly declined for infants of both black and white race (Atlanta: black risk ratio [RR], 0.26 [95% confidence interval {CI}, .17-.38]; white RR: 0.19 [95% CI, .12-.29]; Baltimore: black RR, 0.38 [95% CI, .22-.64]; white RR: 0.51 [95% CI: .29-.90]). Prevalence of fluconazole resistance (7%) was unchanged compared with prior surveillance; 32 (1%) isolates were echinocandin-resistant, and 9 (8 Candida glabrata) were multidrug resistant to both fluconazole and an echinocandin. CONCLUSIONS: We describe marked shifts in candidemia epidemiology over the past 2 decades. Adults aged ≥65 years replaced infants as the highest incidence group; adjusted incidence has declined significantly in infants. Use of antifungal prophylaxis, improvements in infection control, or changes in catheter insertion practices may be contributing to these declines. Further surveillance for antifungal resistance and efforts to determine effective prevention strategies are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All-cause in-hospital mortality of candidemia has been reported as high as 36% in the US.27,51,52”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [51]
In the citing paper
“Candidemia is one of the most common health care–associated BSIs in the United States, with all-cause in-hospital mortality of up to 30%.”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“In population-based surveillance performed in the metropolitan areas of Atlanta, Georgia, and Baltimore, Maryland, candidemia incidence (primarily among adults) increased 10%–40% from the early 1990s and the late 2000s, which was followed by more recent reports of decreases in these areas (6,28–30).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“This contrasts with data from the early 1990s, when infants had the highest incidence (6), followed by substantial decreases by the late 2000s (26,28).”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
In the citing paper
“The previously reported racial disparity in candidemia persisted in this surveillance period (6), with a 2.3 times higher incidence among blacks than among nonblacks.”
From Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016 (2019) · cites this paper as [6]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198 · cited 1×
“%) met criteria for sepsis [19].”
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candida species are among the most common causes of BSIs and are associated with high morbidity and mortality, as well as increases in hospital cost and length of stay [1–5].”
An Intervention to Decrease Catheter-Related Bloodstream Infections in the ICU
Pronovost, P., Needham, D., Berenholtz, S., Sinopoli, D., Chu, H., Cosgrove, S., Sexton, B., Hyzy, R., Welsh, R., Roth, G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061115 · Cited by 4,387 · cited 2×
“…dramatic declines in some central line– associated BSIs (CLABSIs), such as those associated with Staphylococcus aureus , following adherence to established central line insertion practices; however, similar dramatic declines have been less evident for CLABSIs due to Candida species [20, 24, 34–36].”
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M., & Kleijnen, J. (2003) · BMC Medical Research Methodology · doi:10.1186/1471-2288-3-25 · Cited by 3,592
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“shown to decrease risk of disease [21, 25–29].”
Boyle, J. P., Thompson, T. J., Gregg, E. W., Barker, L. E., & Williamson, D. F. (2010) · Population Health Metrics · doi:10.1186/1478-7954-8-29 · Cited by 1,309 · cited 1×
“Increases in common risk factors such as diabetes [30], ICU admissions [31, 32], or numbers of patients receiving immunosuppressive therapies [33] may have resulted in increases in the overall pool of patients at high risk for candidemia.”
Morrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 2×
“0 %) between centres [2, 14, 18, 31] possibly because of lack of standardized criteria.”
Research works printed but not linked: 2
- 1992, Chest, 10, 1644
- 2011, MMWR. Morbidity and mortality weekly report, 60, 243
Cited by
Items 401–411 of 411
Influence of the microbiota on Candida albicans gastrointestinal colonization in healthy individuals
Delavy, M. (2023) · theses.fr (ABES) · doi:10.70675/da5a2f9dz2e64z4e1fz9280z36a010c349be
Candidemia in a tertiary hospital in Southern Brazil
Wilot, L. C., Blan, B. D. S., Poester, V. R., Severo, C. B., Sanchotene, K. O., dos Santos, M. C., Trápaga, M. R., & Xavier, M. O. (2026) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202668027
Candida Drug Resistance in Patients With Diabetic Foot Ulcers: A Systematic Review and Meta‐Analysis
Ekvan, M. H., Sayyadi, H., Alidadpour, S., Karimi, M., Getso, M. I., Ebrahimi, A. R., Mirpanahi, M., & Raiesi, O. (2026) · International Wound Journal · doi:10.1111/iwj.70900
Yoshioka, I., Uchida, M., Kusuya, Y., Shibata, S., Arai, T., Yaguchi, T., Watanabe, A., & Takahashi, H. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00478-26
“By substantially shortening the time to actionable results, this approach has the potential to improve clinical decision-making, optimize antifungal therapy, and reduce morbidity and mortality from fungal BSIs.”
Echeta, M. O., Oyeka, C. A., Nwofor, C., Onyenwe, N. E., Korie, M., Izundu, I. M., & Nzeagwu, M. O. (2021) · SOUTH EASTERN JOURNAL OF RESEARCH AND SUSTAINABLE DEVELOPMENT (SEJRSD)
Structure and function of amphotericin B aggregates
Soutar, C. P. (2023) · Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign)
Wring, S. A., Argent, C., Murphy, G. M., Angulo, D. A., & Middle, M. V. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00961-26
Wang, L.-L., Huang, S.-J., Zhao, J.-T., Liu, J.-Y., & Xiang, M.-J. (2024) · doi:10.3389/fcimb.2023.1321094.s001
Poissy, J. (2014) · theses.fr (ABES) · doi:10.70675/ddead8ccz638fz4c1dz9850z72dc9db47c65
“glabrata) sur 2329 étaient multi-résistantes, à la fois au fluconazole et aux échinocandines [157].”
Background
Metadata
- Authors
- Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M.
- Affiliations
- Centers for Disease Control and Prevention (US)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-14
- Volume
- 55
- Issue
- 10
- Pages
- 1352-1361
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2157512355
- Cited by
- 366
- References
- 138
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 17 · 2023: 16 · 2022: 23 · 2021: 32 · 2020: 35 · 2019: 21 · 2018: 42 · 2017: 35 · 2016: 28 · 2015: 44 · 2014: 33 · 2013: 19 · 2012: 2
- FWCI
- 21.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CC999999)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, candidemia incidence, antifungal resistance, fluconazole resistance, echinocandin resistance, Candida glabrata, multidrug resistance, infants, older adults, epidemiological trends, antifungal prophylaxis, infection control, catheter-related infection, Atlanta, Baltimore
- MeSH terms
- Adolescent, Adult, Aged, Antifungal Agents, Candida, Child, Child, Preschool, Female, Georgia, Humans, Infant, Male, Middle Aged, Population Surveillance, Prospective Studies, Baltimore, Incidence, Drug Resistance, Fungal, Candidemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.